false
0001017491
0001017491
2024-09-24
2024-09-24
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 24, 2024
Seelos Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Nevada |
|
000-22245 |
|
87-0449967 |
(State or Other Jurisdiction of Incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
300
Park Avenue, 2nd Floor,
New York, NY |
|
10022 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: (646) 293-2100
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities Registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Common Stock, $0.001 par value |
SEEL |
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or
Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 8.01. Other Events.
On September
24, 2024, Seelos Therapeutics, Inc. (the "Company") issued a press release titled “Seelos Therapeutics announces the signing
of a Material Transfer Agreement with U.S. Army Medical Materiel Development Activity (USAMMDA) to evaluate SLS-002 for treatment of PTSD.”
A copy of the press release is filed herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Forward-Looking
Statements
The press
release contains forward-looking statements that involve future risks and uncertainties as contemplated by the safe harbor provided by
the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in the Press
Release and Presentation should be regarded as “forward-looking statements.” These forward-looking statements involve known
and unknown risks, uncertainties and other important factors that may cause the actual results, performance or achievements of the Company
to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.
These forward-looking statements are based on the expectations, estimates, projections, beliefs and assumptions of the Company based on
information currently available to it, all of which are subject to change. These forward-looking statements are not guarantees of future
performance and are subject to risks and uncertainties that could cause actual results to differ materially from the results contemplated
by the forward-looking statements. Many of the important factors that will determine these results and values are beyond the Company’s
ability to control or predict. Except as otherwise required by law, the Company does not assume any obligation to update any forward-looking
statements.
For additional
information about factors that could cause actual results to differ materially from those described in the forward-looking statements,
please refer to the Company’s filings with the Securities and Exchange Commission, including the risk factors contained in the Company’s
Annual Report on Form 10-K for the year ended December 31, 2023 and the subsequent Quarterly Reports on Form 10-Q, including the Company’s
Quarterly Report on Form 10-Q for the quarter ended June 30, 2024.
Item 9.01 Financial
Statements and Exhibits
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Seelos Therapeutics,
Inc. |
|
|
Date: September 24, 2024 |
By: |
/s/ Raj Mehra, Ph.D. |
|
|
Name: |
Raj Mehra, Ph.D. |
|
|
Title: |
Chief Executive
Officer and President |
Exhibit 99.1
Seelos Therapeutics announces the signing of a Material Transfer
Agreement with U.S. Army Medical Materiel Development Activity (USAMMDA) to evaluate SLS-002 for treatment of PTSD
-Dosing of the SLS-002 cohort is expected to commence in 4Q2024
NEW YORK, September 24, 2024 /PRNewswire/ -- Seelos
Therapeutics, Inc. (Nasdaq: SEEL) (“Seelos”), a clinical-stage biopharmaceutical company focused on the development
of therapies for central nervous system disorders and rare diseases, today announced the signing of a Material Transfer Agreement (MTA)
with the U.S. Army Medical Materiel Development Activity (USAMMDA) to supply SLS-002 (intranasal racemic ketamine) for the U.S. Department
of Defense's (DOD) Military and Veterans Adaptive Platform Clinical Trial (“M-PACT”) to evaluate its potential for treatment
of post-traumatic stress disorder (PTSD).
Dosing of the SLS-002 cohort is expected to commence prior to the
end of 2024 and it is the only ketamine-based therapy selected for inclusion in this study. The trial is funded by the DOD’s Defense
Health Agency and led by USAMMDA’s Warfighter Readiness, Performance, and Brain Health Project Management Office.
“Approximately 13 million people in the U.S. live with PTSD
and there have been no new drugs approved in the last two decades for people suffering the effects of PTSD,” said Raj Mehra, Ph.D.,
Chief Executive Officer of Seelos. “I believe that the inclusion of SLS-002 in this study is due to the robust amount of anecdotal
evidence that ketamine has the potential to be an effective therapeutic for the symptoms of PTSD and other related conditions. Our data
to date with SLS-002 suggest that its intranasal formulation could provide a rapid onset of benefit while mitigating the side effects
seen through the other routes of administration of ketamine. We are proud to be included in this study and look forward to commencing
the dosing of SLS-002.”
The
DOD M-PACT (NCT05422612) is a Phase II randomized, double-blinded, placebo-controlled study that will evaluate the
safety, tolerability, and efficacy of multiple pharmacotherapeutic interventions in active-duty service members and veterans with PTSD.
The trial utilizes an adaptive platform design that randomizes participants among the multiple treatment cohorts selected for inclusion
in the study and enables sharing of control participants to increase study efficiency. The trial design entails a 30-day screening period,
a 12-week treatment period, and a 4-week safety follow-up. Data will be collected to measure changes in PTSD symptom severity, as measured
by the Clinician-Administered PTSD Scale-5-Revised (CAPS-5-R) and other clinically relevant endpoints. These include the incidence of
new or worsening suicidal thoughts or behaviors, as measured by changes in the Columbia Suicide Severity Rating Scale (C-SSRS) score.
In addition, the trial is evaluating several biomarkers associated with PTSD and assessing treatment safety and tolerability.
For more
information about the M-PACT trial can be found at: https://ptsdclinicaltrial.org/.
About SLS-002
SLS-002 is intranasal racemic ketamine with two investigational new
drug applications for the treatment of Acute Suicidal Ideation and Behavior in Major Depressive Disorder and in Post-Traumatic Stress
Disorder (PTSD). SLS-002 was originally derived from a Javelin Pharmaceuticals, Inc./Hospira, Inc. program with 16 clinical
studies involving approximately 500 subjects. Seelos looks to address an unmet need for a therapy to treat suicidality in the U.S. with
SLS-002. Traditionally, anti-depressants have been used in this setting but many of the existing treatments are known to contribute to
an increased risk of suicidal thoughts in some circumstances, and if they are effective, it often takes weeks for the full therapeutic
effect to be manifested. Based on information gathered from the databases of the Agency for Healthcare Research and Quality, there were
more than 1,000,000 visits to emergency rooms for suicide attempts in 2019 in the U.S. alone. Experimental studies suggest ketamine has
the potential to be a rapid, effective treatment for refractory depression, suicidality and PTSD.
About USAMMDA
The U.S. Army Medical Materiel Development Activity develops,
delivers, and fields critical drugs, vaccines, biologics, devices, and medical support equipment to protect and preserve the lives
of Warfighters across the globe. USAMMDA project managers guide the development of medical products for the U.S. Army Medical
Department, other U.S. military services, the Joint Staff, the Defense Health Agency, and the U.S. Special Operations community. The
process takes promising technology from the Department of Defense, industry, and academia to U.S. Forces, from the testing required
for U.S. Food and Drug Administration approval or licensing to fielding and sustainment of the finished product. USAMMDA Project
Management Offices will transition to a Program Executive Office under the Defense Health Agency, Deputy Assistant Director for
Acquisition and Sustainment.
About Seelos Therapeutics
Seelos Therapeutics, Inc.
is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical
needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. For more information, please visit
our website: https://seelostherapeutics.com, the content of which is not incorporated herein by reference.
No official endorsement of third parties or their products is
made or inferred.
Forward Looking Statements
Statements made in this press release, which are not historical in
nature, constitute forward-looking statements related to Seelos for purposes of the safe harbor provided by the Private Securities Litigation
Reform Act of 1995. These statements include, among others, statements regarding the completion of the offering, the anticipated proceeds
from the offering and the use of such proceeds. For example, the Company is using forward looking statements in this press release when
it discusses the expected timing of the dosing of the study and the study parameters, as well as the belief that the inclusion of SLS-002
in this study is due to the robust amount of anecdotal evidence that ketamine has the potential to be an effective therapeutic for the
symptoms of PTSD and other related conditions. These statements are based on our current expectations and beliefs and are subject to
a number of factors, risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking
statements. The risks and uncertainties involved include those associated with general economic and market conditions and our ability
to satisfy closing conditions applicable to the offering, our intended use of proceeds from the offering, as well as other risk factors
and matters set forth in our periodic filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31,
2023, subsequent Quarterly Reports on Form 10-Q, including Seelos' Quarterly Report on Form 10-Q for the quarter ended June 30,
2024, and the prospectus supplement and the accompanying prospectus related to the public offering to be filed with the SEC. Although
we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations
will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date
hereof, even if subsequently made available by us on our website or otherwise. We do not undertake any obligation to update, amend or
clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required
under applicable securities laws.
Contact Information:
Anthony
Marciano
Chief Communications Officer
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Avenue, 2nd Floor
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com
https://seelostherapeutics.com/
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos
Mike Moyer
Managing Director
LifeSci Advisors, LLC
250 West 55th St., Suite 3401
New York, NY 10019
(617) 308-4306
mmoyer@lifesciadvisors.com
v3.24.3
Cover
|
Sep. 24, 2024 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Sep. 24, 2024
|
Entity File Number |
000-22245
|
Entity Registrant Name |
Seelos Therapeutics, Inc.
|
Entity Central Index Key |
0001017491
|
Entity Tax Identification Number |
87-0449967
|
Entity Incorporation, State or Country Code |
NV
|
Entity Address, Address Line One |
300
Park Avenue
|
Entity Address, Address Line Two |
2nd Floor
|
Entity Address, City or Town |
New York
|
Entity Address, State or Province |
NY
|
Entity Address, Postal Zip Code |
10022
|
City Area Code |
646
|
Local Phone Number |
293-2100
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common Stock, $0.001 par value
|
Trading Symbol |
SEEL
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Seelos Therapeutics (NASDAQ:SEEL)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Seelos Therapeutics (NASDAQ:SEEL)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024